Abstract
We performed a basic evaluation of pazufloxacin (PZFX), a newly developed new quinolone agent, and clinically studied its application in the treatment of respiratory infections, with the following results.
1. Antibacterial activity
The minimum inhibitory concentrations (MICs) of PZFX against 272 strains of 12 species isolated from clinical material were measured and compared with those of other new quinolone agents, ofloxacin (OFLX), tosufloxacin (TFLX) and ciprofloxacin (CPFX). The antimicrobial activity of PZFX for grampositive coccus was the same as that of OFLX and for gram-negative rod was slightly better than those of TFLX and CPFX.
2. Clinical efficacy
Ten patients with respiratory tract infections were given PZFX for 4 to 15 days. Clinical efficacy was assessed as good in 9 cases and poor in 1 case. No side effects were observed.
